The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy

Stopped early · Phase 1/Phase 2

Conditions studied: Lennox-Gastaut Syndrome, Dravet Syndrome

In brief

The investigators propose to study the effects of cannabidiol (CBD) on cardiac electrical function and the autonomic nervous system in children with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), when the CBD is administered as an artisanal oil obtained through state dispensaries or other sources. The intent is to begin to assess potential risks and benefits of this therapy in a vulnerable patient population by characterizing the effects of CBD on EKG findings, heart rate variability and the occurrence of seizures.

Key facts

Study ID

NCT02815540

Run by

Gillette Children's Specialty Healthcare

People needed

2

Starts

2017-02-16

Expected to finish

2018-12-01

Last updated by the study team

2022-08-30

Who can join

Age: 2 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with Dravet syndrome or Lennox-Gastaut syndrome
• Patients who are planning to obtain medical cannabidiol
• Patients who are already taking medical cannabidiol and are planning to stop taking it

You may not qualify if…

• Patients without a diagnosis of Dravet syndrome or Lennox-Gastaut syndrome

Where it is running

• Gillette Children's Specialty Healthcare — Saint Paul, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.